Journal article icon

Journal article

A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.

Abstract:

BACKGROUND: Expression of the DNA repair protein O (6)-methylguanine-DNA methyltransferase (MGMT) correlates with resistance to irinotecan in colorectal cancer cell lines. This phase I study evaluated the maximum tolerated dose (MTD) of lomeguatrib, an inactivating pseudosubstrate of MGMT, in combination with irinotecan in patients with metastatic colorectal cancer and assessed the safety, toxicity and clinical pharmacology of combination treatment. PATIENTS AND METHODS: Patients with metast...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1007/s00280-009-1225-0

Authors


Expand authors...
Journal:
Cancer chemotherapy and pharmacology
Volume:
66
Issue:
5
Pages:
829-835
Publication date:
2010-10-05
DOI:
EISSN:
1432-0843
ISSN:
0344-5704
URN:
uuid:bef9754d-d351-4f0e-aee6-489c8e04732e
Source identifiers:
120117
Local pid:
pubs:120117

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP